In a surprising rebuttal of previous findings, a new study shows that African Americans with multiple myeloma have an overall higher survival rate than Caucasians with the disease when all patients have equal access to cutting-edge therapies. The results raise questions about the biology of this type of cancer. Multiple myeloma, a cancer that arises … Read more
Medically reviewed by Kornelia Polyak, MD, PhD In the jostling, jockeying mob of cell populations within a malignant tumor, the most inconspicuous groups can be the most dangerous. In a new study, Dana-Farber scientists show that in some breast cancers, two small factions of cells cooperate to drive metastasis but don’t directly interact with each … Read more
Scientists have discovered a previously unknown mechanism in mice that influences their ability to feel pain. The discovery suggests the possibility of new approaches to treating pain in humans that are an alternative to opioid drugs. The scientists, reporting in the journal Science, found that the production of prostaglandins in white blood cells depends on … Read more
Designed to subvert tumor cells from within, a growing number of cancer drugs have also been found to have other talents. In the last few years, scientists have discovered that targeted drugs known as CDK4/6 inhibitors and certain chemotherapy agents not only hamper the internal workings of cancer cells but can also make them the … Read more
Like ambitious cartographers bent on mapping entire countries down to their individual houses, scientists are using state-of-the-art methods to create two mammoth atlases — one aimed at mapping human cells of every type, and the other a 3D atlas of every molecular feature of cancer as it develops, spreads, and responds to treatment. The Human … Read more
Crowdsourcing is an increasingly powerful approach for fueling innovation in many sectors but has not been routinely applied in academic medicine. Scientists at Dana-Farber/Harvard Cancer Center are exploring ways to harness this method for solutions to pressing clinical problems, such as the worldwide shortage of radiation oncologists. Their work has led to the development of … Read more
Medically reviewed by Himisha Beltran, MD Prostate cancer, when diagnosed early, can be a very treatable disease. Even advanced prostate cancer has treatment options. But some advanced, metastatic prostate cancers become resistant to standard therapies by shapeshifting into a different type of cancer, called small cell neuroendocrine prostate cancer. These neuroendocrine tumors tend to be … Read more
Medically reviewed by Laurie H. Glimcher, MD, and Rizwan Romee, MD Immune cells called natural killer (NK) cells are a key arm of the body’s defenses against infections and cancers, but what provokes them into action is less well understood than some other immune components such as T cells. “Critical gaps in our knowledge regarding … Read more
Many of the drugs that have become mainstays of cancer treatment are based on antibodies — artificial proteins that latch onto a molecular target called an antigen. When an antibody binds to an antigen on a cancer cell, it attacks the cell or triggers its destruction by immune system process. A relatively new twist on … Read more
In the annals of patients who have benefited from Dana-Farber and Brigham and Women’s Hospital’s (BWH) genomic sequencing program Profile, few involve a turnabout as dramatic as one recently reported in Gynecologic Oncology. Authored by nearly a dozen Dana-Farber and BWH faculty, the paper recounts the medical history of a 49-year-old Nebraska woman first diagnosed … Read more
Cancer is often fueled by hormones, including the male sex hormone testosterone, which spur tumor growth in most forms of prostate cancer. Doctors can defuse this destructive relationship, typically with drugs (or sometimes surgery), but frequently, the tumors adapt or evolve, devising ways to incite cancer growth even in the absence of hormone-driven signals. These … Read more
The process of converting genetic information from DNA to RNA, known as transcription, is a joint undertaking. Sections of DNA, known as promoters, collaborate with other sections known as enhancers to recast the genetic code into a form that can be used by cells to make proteins. As with many partnerships, however, it hasn’t been … Read more
Women who are obese have nearly double the risk of developing colorectal cancer at a young age than women with a normal body mass index, a recent study by investigators at Dana-Farber and other institutions has found. The study, prompted by concerns over recent increases in colorectal cancer rates in people under 50, is the … Read more
On the strength of the results of a major international clinical trial, there is now a new standard of care for patients with an advanced form of ovarian cancer who have responded to initial chemotherapy. The trial, dubbed SOLO-1, found that these patients – newly diagnosed with ovarian cancer that carries a mutation in the … Read more
High-tech devices that flow cancer cells over a miniaturized “scale” to measure changes in the weight of single living cells are increasingly being used to test the susceptibility of cancer cells to different drugs. The devices are so sensitive that they can measure a change in growth rate of a cell within hours or days … Read more
Six years’ worth of repeated surgeries, radiation, and chemotherapy with three different agents failed to halt the growth of Frances Zichichi’s brain tumor. As it kept recurring and more surgeries were required, Zichichi lost the use of her left side. Eventually the cancer formed masses under her scalp, causing pain, which was dulled only with … Read more
One of the biggest challenges in treating cancer is that the cells making up a tumor – say a breast or lung tumor – are enormously diverse, or heterogeneous. This tumor heterogeneity can be both genetic, meaning the DNA in the tumor cells differs from one cell to the next, and epigenetic, meaning that the … Read more
Breast cancer research makes possible the development of new therapies for breast cancer. Through clinical trials and work in research labs, including those at Dana-Farber Cancer Institute, treatments and drugs are explored — and if successful, are later able to be offered to patients who need them. Breast cancer today is seen as not one, … Read more
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Read more